Combination of an HDAC inhibitor and an antimetabolite

Details for Australian Patent Application No. 2007328281 (hide)

Owner Novartis AG

Inventors Atadja, Peter Wisdom

Agent Davies Collison Cave

Pub. Number AU-B-2007328281

PCT Pub. Number WO2008/070011

Priority 60/868,388 04.12.06 US

Filing date 30 November 2007

Wipo publication date 12 June 2008

Acceptance publication date 31 March 2011

International Classifications

A61K 31/4045 (2006.01)

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

28 May 2009 PCT application entered the National Phase

  PCT publication WO2008/070011 Priority application(s): WO2008/070011

31 March 2011 Application Accepted

  Published as AU-B-2007328281

28 July 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007328286-Inhibitors of Akt activity

2007328280-Hydroxylamine derivatives for the treatment of stroke